Heptares appoints Tim Tasker as chief medical officer

pharmafile | January 16, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Heptares, tim tasker 

Drug development firm Heptares Therapeutics has appointed Dr Tim Tasker as its chief medical officer (CMO) and VP of Development.

Tasker will lead the company’s clinical development activities and takes over from Dr David McGibney, who returns to his role as a senior clinical advisor at the firm.

Tasker is a doctor and clinical pharmacologist with more than 30 years of industry experience from both large pharma and small biotech companies. 

He spent over 20 years at GlaxoSmithKline and led all of its Phase I clinical research units (in the US, UK, Europe and Australia). After GSK, he joined Evotec as executive VP of clinical development.

Heptares chief executive Malcolm Weir said: “It reflects well on Heptares that we have been able to attract a CMO of Tim’s calibre and reputation. His experience in developing new compounds from pre-clinical into clinical development is a valuable addition to Heptares as we dedicate increasing efforts to advancing our rich pipeline of GPCR-targeted medicines.” 

Related Content


AstraZeneca trigger $10 million milestone payment for Heptares in immuno-oncology candidate

AstraZeneca (LSE: AZN) is set to deliver a payment of $10 million to Heptares Therapeutics …


Allergan to partner with Heptares in Alzheimer’s disease collaboration

Bouncing back quickly from the collapse of the collapse of the Pfizer inversion deal, Allergan …


Heptares announces positive early-stage dementia trial results

Heptares has announced positive findings from its Phase 1b clinical study with its investigational drug …

Latest content